CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
28 hedge funds and large institutions have $2.29M invested in CASI Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
19% more capital invested
Capital invested by funds: $1.92M → $2.29M (+$364K)
7% less funds holding
Funds holding: 30 → 28 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSCM
Wellington Shields Capital Management
New York
|
+$93K |
| 2 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$53.4K |
| 3 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
+$14.6K |
| 4 |
MC
Moors & Cabot
Boston,
Massachusetts
|
+$13.5K |
| 5 |
Renaissance Technologies
New York
|
+$5.23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$14K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.54K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$2.09K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
CASI Hedge Fund Activity: Q1 2016 in Review
28 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q1 2016, worth a combined $2.29M — up 19% from $1.92M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CASI and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 9 added.
The largest buyer was Wellington Shields Capital Management, adding an estimated $93K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $14K sold.
- 28 institutional investors held CASI Pharmaceuticals (CASI) as of Q1 2016, down from 30 in Q4 2015.
- Funds reported $2.29M of CASI Pharmaceuticals stock for Q1 2016, up 19% quarter-over-quarter.
- 2 funds opened new CASI Pharmaceuticals positions in Q1 2016 and 4 closed out, a net change of -2 holders.
- The largest CASI Pharmaceuticals buyer in Q1 2016 was Wellington Shields Capital Management, an estimated $93K added.
- The largest CASI Pharmaceuticals seller in Q1 2016 was Virtu KCG Holdings, an estimated $14K sold.
Based on aggregated 13F filings for Q1 2016.